Nima Farzan
CIK: 0001808296
Associated companies
Transaction History
| KROS | ▼ Sell | Open Market | 2,625 | $28K | 6/4/2026 | View on chart |
| KROS | ▲ Buy | Grant | 7,142 | $0 | 6/3/2026 | View on chart |
| KROS | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 | View on chart |
| KROS | ▼ Sell | Open Market | 2,625 | $28K | 6/4/2026 | View on chart |
| KROS | ▲ Buy | Grant | 7,142 | $0 | 6/3/2026 | View on chart |
| KROS | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial
Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.